The 5-year survival rate of patients with CD133-negative tumours was 23.5%, that of patients with less than 5% CD133-positive cells was 3.4%, and that of patients with more than 5% CD133-positive cells was 0.0%. This evidence concerns the gene PROM1 and neoplasm.